BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Update

BioLineRx Ltd. (NASDAQ:BLRX) was the recipient of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 621,400 shares, an increase of 351.3% from the September 30th total of 137,700 shares. Based on an average trading volume of 285,400 shares, the short-interest ratio is presently 2.2 days.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on BioLineRx in a report on Wednesday. They set a “hold” rating on the stock.

Hedge Funds Weigh In On BioLineRx

A hedge fund recently bought a new stake in BioLineRx stock. PVG Asset Management Corp acquired a new position in shares of BioLineRx Ltd. (NASDAQ:BLRX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 123,580 shares of the biotechnology company’s stock, valued at approximately $70,000. PVG Asset Management Corp owned 0.15% of BioLineRx at the end of the most recent quarter. 1.56% of the stock is currently owned by hedge funds and other institutional investors.

BioLineRx Trading Up 1.3 %

Shares of NASDAQ:BLRX traded up $0.01 during midday trading on Friday, reaching $0.41. The company had a trading volume of 362,561 shares, compared to its average volume of 345,530. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.49 and a current ratio of 1.61. BioLineRx has a 1-year low of $0.39 and a 1-year high of $1.93. The firm has a market cap of $32.38 million, a price-to-earnings ratio of -0.53 and a beta of 1.46. The company has a fifty day simple moving average of $0.58 and a two-hundred day simple moving average of $0.64.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings results on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The company had revenue of $5.39 million during the quarter, compared to analyst estimates of $3.93 million. Research analysts predict that BioLineRx will post -0.25 earnings per share for the current year.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.